FY2027 EPS Forecast for Pharming Group Lifted by Analyst

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Investment analysts at HC Wainwright raised their FY2027 earnings per share estimates for shares of Pharming Group in a research note issued to investors on Thursday, October 22nd. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of $0.56 per share for the year, up from their previous estimate of $0.54. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group’s current full-year earnings is $0.22 per share.

Other equities research analysts have also issued reports about the company. Weiss Ratings restated a “sell (d)” rating on shares of Pharming Group in a research report on Friday, August 7th. Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a research note on Thursday, July 30th. Canaccord Genuity Group set a $38.00 price target on Pharming Group in a research report on Wednesday, September 23rd. Finally, Zacks Research lowered Pharming Group from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $38.67.

Pharming Group Stock Performance

NASDAQ:PHAR opened at $10.67 on Friday. The company has a market cap of $755.22 million, a P/E ratio of 88.92 and a beta of -0.05. Pharming Group has a twelve month low of $9.11 and a twelve month high of $21.34. The company’s 50-day moving average price is $10.68 and its 200-day moving average price is $12.63. The company has a current ratio of 3.01, a quick ratio of 2.31 and a debt-to-equity ratio of 0.34.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%.

Institutional Trading of Pharming Group

An institutional investor recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP acquired a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group comprises about 6.0% of MAC Alpha Capital Management LP’s investment portfolio, making the stock its 2nd largest position. MAC Alpha Capital Management LP owned approximately 3.03% of Pharming Group as of its most recent filing with the SEC. 0.03% of the stock is owned by institutional investors.

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.